NASDAQ:BCRX BioCryst Pharmaceuticals (BCRX) Stock Price, News & Analysis $8.77 -0.20 (-2.23%) Closing price 04:00 PM EasternExtended Trading$8.93 +0.16 (+1.81%) As of 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About BioCryst Pharmaceuticals Stock (NASDAQ:BCRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BCRX alerts:Sign Up Key Stats Today's Range$8.73▼$9.0150-Day Range$8.22▼$9.8952-Week Range$6.00▼$11.31Volume3.88 million shsAverage Volume5.20 million shsMarket Capitalization$2.23 billionP/E RatioN/ADividend YieldN/APrice Target$20.70Consensus RatingModerate Buy Company Overview BioCryst Pharmaceuticals, Inc. is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms. The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe. Orladeyo represents BioCryst’s entry into the specialty pharmaceutical market and offers an alternative to injectable prophylactic therapies, with the goal of reducing the frequency of HAE attacks and improving patient convenience. In addition to its approved product, BioCryst is advancing a pipeline of investigational candidates, including BCX9930, an oral factor D inhibitor being studied for complement‐mediated diseases, and BCX10013, a novel kallikrein inhibitor under development for the treatment of acute HAE attacks. The company’s research and development efforts extend from preclinical stages through multiple phases of clinical trials, with a focus on expanding its small‐molecule platform to address additional rare and serious conditions. Under the leadership of President and CEO Jon P. Stonehouse, BioCryst maintains a global orientation, collaborating with regulatory authorities and commercial partners in North America, Europe, and select international markets. The company’s headquarters in Durham support its research, development, and administrative functions, while strategic alliances and distribution agreements help facilitate patient access to its therapies worldwide.AI Generated. May Contain Errors. Read More BioCryst Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks74th Percentile Overall ScoreBCRX MarketRank™: BioCryst Pharmaceuticals scored higher than 74% of companies evaluated by MarketBeat, and ranked 181st out of 851 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingBioCryst Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on no strong buy ratings, 9 buy ratings, 3 hold ratings, and no sell ratings.Upside PotentialBioCryst Pharmaceuticals has a consensus price target of $20.70, representing about 136.2% upside from its current price of $8.77.Amount of Analyst CoverageBioCryst Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about BioCryst Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth87.10% Earnings GrowthEarnings for BioCryst Pharmaceuticals are expected to grow by 87.10% in the coming year, from $0.31 to $0.58 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioCryst Pharmaceuticals is -4.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioCryst Pharmaceuticals is -4.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about BioCryst Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted15.51% of the float of BioCryst Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverBioCryst Pharmaceuticals has a short interest ratio ("days to cover") of 11.11, which indicates bearish sentiment.Change versus previous monthShort interest in BioCryst Pharmaceuticals has recently decreased by 2.90%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBioCryst Pharmaceuticals does not currently pay a dividend.Dividend GrowthBioCryst Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.5 / 5News Sentiment-0.06 News SentimentBioCryst Pharmaceuticals has a news sentiment score of -0.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.37 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for BioCryst Pharmaceuticals this week, compared to 6 articles on an average week.Search Interest28 people have searched for BCRX on MarketBeat in the last 30 days. This is an increase of 8% compared to the previous 30 days.MarketBeat Follows6 people have added BioCryst Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, BioCryst Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,372,500.00 in company stock.Percentage Held by Insiders5.10% of the stock of BioCryst Pharmaceuticals is held by insiders.Percentage Held by Institutions85.88% of the stock of BioCryst Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about BioCryst Pharmaceuticals' insider trading history. Receive BCRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioCryst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BCRX Stock News HeadlinesHC Wainwright Issues Pessimistic Estimate for BCRX EarningsMay 18 at 2:31 AM | americanbankingnews.comBioCryst Pharmaceuticals Inc.May 14, 2026 | barrons.comThe 1934 playbookIn 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it coming — but those who did walked away wealthy.Trump holds that same legal authority today. Advisors close to the administration believe he may use it.If he does, the transfer moves fast. The window to position yourself on the right side is already closing.May 19 at 1:00 AM | American Alternative (Ad)BioCryst (BCRX) Is Down 6.7% After Q1 Loss And Navenibart Deal News Has The Bull Case Changed?May 13, 2026 | uk.finance.yahoo.comA Look At BioCryst Pharmaceuticals (BCRX) Valuation After Q1 Results And Navenibart Licensing DealMay 13, 2026 | finance.yahoo.comBioCryst Pharmaceuticals to Present New Research on Pediatric Hereditary Angioedema at ISPOR 2026 ConferenceMay 13, 2026 | quiverquant.comQBioCryst to Present New Real-World Evidence Underscoring the Ongoing Burden of Pediatric Hereditary Angioedema at ISPOR 2026May 13, 2026 | globenewswire.comBioCryst Pharmaceuticals Sees ORLADEYO, Astria Deal Driving Rare Disease GrowthMay 13, 2026 | americanbankingnews.comSee More Headlines BCRX Stock Analysis - Frequently Asked Questions How have BCRX shares performed this year? BioCryst Pharmaceuticals' stock was trading at $7.80 at the beginning of 2026. Since then, BCRX shares have increased by 12.4% and is now trading at $8.7650. How were BioCryst Pharmaceuticals' earnings last quarter? BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) released its earnings results on Wednesday, May, 6th. The biotechnology company reported ($2.98) earnings per share for the quarter, missing analysts' consensus estimates of $0.06 by $3.04. The firm's revenue for the quarter was up 7.5% compared to the same quarter last year. Read the conference call transcript. Who are BioCryst Pharmaceuticals' major shareholders? Top institutional investors of BioCryst Pharmaceuticals include Janus Henderson Group PLC (3.51%), Bank of America Corp DE (2.00%), Eversept Partners LP (1.20%) and RFG Advisory LLC (1.14%). Insiders that own company stock include Alane P Barnes, Helen M Thackray, Anthony Doyle, Nancy J Hutson, Theresa Heggie, Steven K Galson, Alan G Levin, Amy E Mckee, Machelle Sanders and Steve Aselage. View institutional ownership trends. How do I buy shares of BioCryst Pharmaceuticals? Shares of BCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of BioCryst Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioCryst Pharmaceuticals investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Netflix (NFLX), Pfizer (PFE) and PayPal (PYPL). Company Calendar Last Earnings5/06/2026Today5/19/2026Jefferies Global Healthcare Conference 20266/03/2026Next Earnings (Estimated)8/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 BCRX's financial health is in the Green zone, according to TradeSmith. BCRX has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryBiotechnology Current SymbolNASDAQ:BCRX CIK882796 Webwww.biocryst.com Phone(919) 859-1302Fax919-859-1314Employees530Year Founded1986Price Target and Rating Average Price Target for BioCryst Pharmaceuticals$20.70 High Price Target$32.00 Low Price Target$9.00 Potential Upside/Downside+136.0%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($1.78) Trailing P/E RatioN/A Forward P/E Ratio28.29 P/E GrowthN/ANet Income$263.86 million Net Margins-51.71% Pretax Margin-51.28% Return on Equity-76.36% Return on Assets60.12% Debt Debt-to-Equity RatioN/A Current Ratio1.91 Quick Ratio1.88 Sales & Book Value Annual Sales$874.84 million Price / Sales2.55 Cash Flow$1.20 per share Price / Cash Flow7.29 Book Value($0.57) per share Price / Book-15.39Miscellaneous Outstanding Shares254,160,000Free Float241,201,000Market Cap$2.23 billion OptionableOptionable Beta0.57 Social Links 7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:BCRX) was last updated on 5/19/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioCryst Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioCryst Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
